Cervical lipomatosis in HIV-infected patients:: a case-control study

被引:5
作者
Palacios, R.
Galindo, M. J.
Arranz, J. A.
Lozano, F.
Estrada, V.
Rivero, A.
Morales, D.
Asensi, V.
del Arco, A.
Munoz, A.
Santos, J.
机构
[1] Hosp Virgen Victoria, Unidad Infermedades Infecciosas, Infect Dis Unit, Malaga 29010, Spain
[2] Gen Hosp, Infect Dis Unit, Valencia, Spain
[3] Hosp Principe Asturias, Internal Med Serv, Alcala De Henares, Spain
[4] Hosp Valme, Infect Dis Unit, Seville, Spain
[5] Hosp Clin San Carlos, Infect Dis Unit, Madrid, Spain
[6] Hosp Reina Sofia, Infect Dis Unit, Cordoba, Spain
[7] Hosp Virgen Macarena, Infect Dis Unit, Seville, Spain
[8] Hosp Gen Asturias, Internal Med Serv, E-33006 Oviedo, Spain
[9] Hosp Costa Sol, Internal Med Serv, Marbella, Spain
[10] Hosp Infanta Cristina, Infect Dis Unit, Badajoz, Spain
关键词
antiretroviral therapy; buffalo hump; cervical lipomatosis; HIV infection; lipodystrophy;
D O I
10.1111/j.1468-1293.2007.00421.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives The aim of the study was to analyse the prevalence of cervical lipomatosis (CL) in HIV-infected patients on highly active antiretroviral therapy (HAART) and the factors associated with its development. Methods This was a multicentre, observational, 1:1 case-control study. HIV-infected patients with CL (cases) and HIV-infected patients from the same cohort, controlled for age (+/- 5 years), sex and body mass index (+/- 2.5 kg/m(2)) (controls), were included in the study, and a multiple conditional logistic regression was performed to identify factors related to CL. Results CL was reported in 80 patients (1.8%) from a cohort of 4214 patients on HAART followed up in 10 Spanish hospitals. CL was associated with time of exposure to stavudine [for each 6-month increase, odds ratio (OR) 5.82, 95% confidence interval (CI) 5.70-5.94, P=0.0073] and lipoatrophy (OR 8.04, 95% CI 2.93-22.02, P=0.00001). Conclusions Although lipodystrophy is very frequent among HIV-infected patients on HAART, CL is an uncommon type of fat redistribution in this population, and in our cohort it was related to time of exposure to stavudine and lipoatrophy.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 24 条
[1]   Lipodystrophy syndrome in HIV infection - What is it, what causes it and how can it be managed? [J].
Behrens, GMN ;
Stoll, M ;
Schmidt, RE .
DRUG SAFETY, 2000, 23 (01) :57-76
[2]   Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs - The Swiss HIV cohort study [J].
Bernasconi, E ;
Boubaker, K ;
Junghans, C ;
Flepp, M ;
Furrer, HJ ;
Haensel, A ;
Hirschel, B ;
Boggian, K ;
Chave, JP ;
Opravil, M ;
Weber, R ;
Rickenbach, M ;
Telenti, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) :50-55
[3]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[4]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy [J].
Gervasoni, C ;
Ridolfo, AL ;
Trifirò, G ;
Santambrogio, S ;
Norbiato, G ;
Musicco, M ;
Clerici, M ;
Galli, M ;
Moroni, M .
AIDS, 1999, 13 (04) :465-471
[7]   Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome [J].
Grinspoon, S .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S85-S90
[8]   Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome [J].
Grunfeld, C ;
Tien, P .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S43-S46
[9]   Benign symmetric lipomatosis associated with protease inhibitors [J].
Hengel, RL ;
Watts, NB ;
Lennox, JL .
LANCET, 1997, 350 (9091) :1596-1596
[10]   Suprasellar adrenocorticotropic hormone-secreting ectopic pituitary adenoma: Case report and literature review [J].
Hou, L ;
Harshbarger, T ;
Herrick, MK ;
Tse, V .
NEUROSURGERY, 2002, 50 (03) :618-625